ArticleJournal of sickle cell disease2026
Ciliary protein ARL13b detected on RBCs as a potential indicative biomarker of vaso-occlusive crisis and disease severity in SCD: a retrospective pilot study.
Article in Journal of sickle cell disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Objectives: Assessing SCD phenotype is challenging, hindering progress in care and quality of life. Pain crises are the hallmark of SCD, but no reliable prognostic biomarker exists due to its complex pathophysiology. ADP-ribosylation factor-like protein 13b (ARL13b), a small GTPase localized to primary cilia, is present on sickle RBCs and in plasma, therefore RBC-bound ARL13b may thus predict pain crises in SCD. Methods: Blood samples from SCD patients were analyzed for ARL13b on RBCs and soluble ARL13b (sARL13b). Retrospective chart reviews tracked hospitalizations for pain crises within 3 months before and after enrollment, hemolysis markers (hemoglobin, bilirubin, lactate dehydrogenase), and disease severity indicators (crisis frequency, acute chest syndrome, kidney disease, cerebrovascular accident). Correlations were calculated between ARL13b measures, pain crises, hemolysis, and severity. Results: In our pilot study, significant correlations existed between the percentage of RBCs carrying ARL13b measured on the day of enrollment, and the number of pain crisis experienced by the patients during the 3 months following enrollment ( Conclusion: In this exploratory study, ARL13b detected on sickle RBCs provides not only an objective prognostic biomarker of pain crisis, but also a potentially unbiased predictor of SCD severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.